The clinical spectrum of kidney adverse effects of VEGF inhibitors (VEGFi) is composed by a new-onset or exacerbation of HTN, proteinuria (sometimes in nephrotic range) and TMA with severe AKI. This evidence concerns the gene VEGFA and acute kidney injury.